Retatrutide, a new dual activator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) receptor , is showing promising outcomes in preliminary human trials . Recent research https://bookmarklethq.com/story21336139/retatrutide-emerging-studies-and-potential-clinical-uses